Business Context and Reporting Period
Company: The Cooper Companies, Inc. (Cooper)
Filing Type: Form 10-K (Annual Report)
Period Ended: October 31, 2008
Business Overview: Cooper operates through two primary segments: CooperVision, Inc. (CVI), a global manufacturer of soft contact lenses (spherical, toric, and multifocal), and CooperSurgical, Inc. (CSI), a developer of medical devices for obstetrics and gynecology. The company is a large accelerated filer incorporated in Delaware.
Key Financial Metrics
| Metric | Fiscal 2008 | Fiscal 2007 | Change |
|---|---|---|---|
| Net Sales | $1,063.2 million | $950.6 million | +12% |
| Gross Profit | $610.0 million | $519.5 million | +17% |
| Gross Margin | 57.4% | 54.6% | +280 bps |
| Operating Income | $127.0 million | $45.9 million | +177% |
| Net Income | $65.5 million | $(11.2) million | Turnaround to Profit |
| Diluted EPS | $1.43 | $(0.25) | N/A |
| Operating Cash Flow | $96.5 million | $134.0 million | -28% |
| Total Debt | $904.8 million | $876.6 million | +3% |
| Cash & Equivalents | $1.9 million | $3.2 million | -41% |
Material Changes vs. Prior Period
- Profitability Recovery: The company returned to profitability in 2008 ($65.5M net income) compared to a net loss of $11.2M in 2007. This was driven by a significant reduction in restructuring and integration costs (down from $119.1M in 2007 to $41.3M in 2008) and improved operating leverage.
- Revenue Growth: Consolidated sales grew 12%. CVI sales increased 12% driven by silicone hydrogel lenses (Biofinity and Avaira) and single-use products. CSI sales grew 9% with 6% organic growth.
- Margin Expansion: Gross margin improved to 57% from 55%, aided by manufacturing efficiencies and a shift in product mix, despite higher costs associated with new silicone hydrogel production.
- Segment Performance: CVI operating income surged to $123.4M from $57.2M. CSI operating income rose to $32.7M from $20.1M.
Guidance, Outlook, and Risks
Outlook: Management lowered expectations for fiscal 2009 due to the global economic downturn, recessionary pressures, and tighter credit markets. Slower sales were observed in October and November 2008. However, the company remains optimistic about long-term demographics and the shift toward specialty and silicone hydrogel lenses.
Capital Allocation: Capital expenditures for 2009 are projected at $125M–$140M, primarily for expanding silicone hydrogel manufacturing capacity and IT systems. The company expects to fund operations via cash flow and its $650M credit facility ($138.4M available as of Oct 31, 2008).
Key Risks:
- Economic Conditions: Potential decline in demand for contact lenses due to consumer spending cuts and credit market instability.
- Goodwill Impairment: Stock price volatility and trading below book value create a risk of future goodwill impairment charges, though no impairment was recorded as of Oct 31, 2008.
- Competition: Intense competition in the silicone hydrogel market from larger rivals (Johnson & Johnson, CIBA Vision, Bausch & Lomb).
- Supply Chain: Reliance on a single supplier (Asahi) for the primary silicone hydrogel material (comfilcon A).
- Legal Proceedings: Ongoing securities class action litigation regarding the Ocular Sciences merger and patent infringement litigation with Bausch & Lomb.
Investor Verification Checklist
- Goodwill Valuation: Verify the assumptions used in the interim goodwill impairment test given the stock price decline below book value.
- Inventory Levels: Review the increase in inventory months-on-hand (8.0 months in 2008 vs. 5.9 in 2007) to ensure it aligns with new product launch strategies and does not signal obsolescence risk.
- Debt Covenants: Confirm continued compliance with the Interest Coverage Ratio (5.14:1) and Total Leverage Ratio (3.46:1) under the credit facility.
- Legal Exposure: Monitor the status of the securities class action lawsuit and the Bausch & Lomb patent dispute for potential settlement costs or injunctions.
- Silicone Hydrogel Ramp: Assess the timeline and cost efficiency of the Biofinity and Avaira manufacturing ramp-up, as these are critical for future margin expansion.